Although it has been reported that TP53 pathogenic variants are factors of poor prognosis for B-cell acute lymphoblastic leukemia [80], evidence of resistance of LFS-associated cancers to treatment are limited; thus, standard treatment of each cancer is prioritized. Here, TP53 is linked to cancer.